Orion Corporation Secures Exclusive License for Novel Antibody
Orion Corporation Secures Exclusive License for Novel Antibody
Orion Corporation and Abzena are thrilled to announce a significant partnership, marking a new chapter in the fight against cancer through an exclusive commercial license agreement. This arrangement affords Orion access to a unique monoclonal antibody (mAb) developed by Abzena, a leader in the end-to-end integrated Contract Development and Manufacturing Organization (CDMO) for biologics and bioconjugates.
Focus on Oncology
The antibody that Orion has licensed is specifically designed to target a high clinical need in oncology. This advancement is set to enhance Orion's ongoing research and development efforts in oncology, a core area of focus for the company. By integrating this novel therapeutic into their pipeline, Orion is poised to offer patients more effective treatment options and advance their mission of improving patient well-being.
Innovation through Partnership
Abzena's state-of-the-art technology, known as Composite Human Antibody (CHAb™), was instrumental in creating this promising lead candidate. The antibody was crafted at Abzena's advanced R&D facility in the UK, utilizing a proprietary approach that emphasizes the safety, functionality, and manufacturability of the antibody. The rigorous screening process employed ensured that only the most robust candidates were chosen for further development.
The Development Process
Leveraging the AbZelectPRO™ cell line development platform, Abzena succeeded in generating a stable and productive manufacturing cell line specifically for this mAb. This cutting-edge development approach not only streamlines manufacturing but also enhances the reliability of the antibody as it progresses through clinical trials.
Statements from Orion and Abzena Leadership
Campbell Bunce, Chief Scientific Officer at Abzena, expressed enthusiasm at the partnership with Orion, stating, “We are delighted to collaborate with Orion on developing our CHAb-designed mAb. Our integrated development approach facilitated the design of a de-risked lead antibody, thereby increasing its chances of success in clinical settings.”
Collaboration Value
Antti Haapalinna, Orion’s Vice President for External Science and Partnering in R&D, echoed similar sentiments: “Our collaboration with Abzena has been exceptional. The transparency and expertise they brought to the project have yielded promising results.” This collaborative spirit is vital in pushing the boundaries of what’s possible in the field of oncology.
Abzena’s Expertise
With over two decades of experience in the biopharmaceutical landscape, Abzena has established itself as a frontrunner in the design, development, and manufacture of monoclonal antibody programs. Their capabilities allow them to support initiatives in both the Cambridge and San Diego facilities, ensuring that high standards for process development and GMP manufacturing are met.
About Orion Corporation
Orion has been a key player in the pharmaceutical sector for over a century, dedicated to fostering well-being globally. The company specializes in the development and marketing of both human and veterinary pharmaceuticals, as well as active pharmaceutical ingredients. Orion’s expansive portfolio includes both proprietary and generic medicines targeting diverse therapeutic areas, particularly in oncology, pain management, and neurology.
Growth and Commitment
In the past financial year, Orion reported impressive net sales, reflecting their strong market presence and commitment to advancing healthcare solutions. The company boasts a dedicated workforce of approximately 3,700 professionals committed to their mission: enhancing well-being.
Contact Information
If you have any inquiries regarding this partnership or Orion's initiatives, please reach out to Antti Haapalinna, Vice President of External Science and Partnering, R&D at Orion Corporation. You can contact him at +358 50 966 7670.
Frequently Asked Questions
What is the focus of Orion Corporation's development pipeline?
Orion Corporation's development pipeline primarily focuses on oncology, aiming to provide innovative treatments for cancer patients.
Who developed the monoclonal antibody licensed by Orion?
The monoclonal antibody was developed by Abzena using their proprietary Composite Human Antibody (CHAb™) technology.
What is the significance of the AbZelectPRO™ platform?
The AbZelectPRO™ platform is essential as it aids in creating highly stable and productive manufacturing cell lines for antibodies, ensuring efficient production.
How long has Abzena been in the biopharmaceutical industry?
Abzena has over 20 years of experience in designing, developing, and manufacturing monoclonal antibody programs.
What is Orion's global presence?
Orion is a globally operating pharmaceutical company with a significant workforce dedicated to research and development, manufacturing, and marketing across the world.
About The Author
Contact Addison Perry privately here. Or send an email with ATTN: Addison Perry as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
